MAM
TERN

Martingale Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Martingale Asset Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-83,038
Closed -$229K – 855
2025
Q1 		$229K Sell
83,038
-15,068
-15% -$61.5K 0.01% 723
2024
Q4 		$544K Buy
98,106
+24,033
+32% +$163K 0.01% 590
2024
Q3 		$618K Buy
+74,073
New +$609K 0.01% 584
2024
Q1 		– Sell
-15,469
Closed -$100K – 863
2023
Q4 		$100K Buy
+15,469
New +$81.8K ﹤0.01% 777

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Martingale Asset Management's TERN Position: Q2 2025 in Review

Martingale Asset Management sold out of Terns Pharmaceuticals (TERN) in Q2 2025, closing a stake of 83,038 shares — an estimated $229K sold.

Martingale Asset Management first reported a position in TERN in Q4 2023 and held it in 4 quarters. The position peaked at $618K in Q3 2024. 129 funds tracked by Wall St. Rank hold TERN as of Q2 2025.

  • Martingale Asset Management reported no remaining Terns Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Martingale Asset Management sold 83,038 Terns Pharmaceuticals shares in Q2 2025, an estimated $229K.
  • Martingale Asset Management first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Martingale Asset Management's Terns Pharmaceuticals position peaked at $618K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2025.

Based on Martingale Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.